POS1022 RELATIONSHIPS BETWEEN INHIBITION OF RADIOGRAPHIC PROGRESSION AND ACHIEVEMENT OF LOW DISEASE ACTIVITY OR REMISSION AND THEIR CORE COMPONENTS IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB IN FUTURE 5 DURING THE FIRST 24 WEEKS
Authors: P. J. Mease, A. M. Orbai, B. Parikh, C. Gaillez, X. Meng, C. T. Ritchlin
Journal: Annals of the Rheumatic Diseases (2022)

Background Patients with active psoriatic arthritis (PsA) experience inflammation that may result in structural damage and disability. In the phase 3 FUTURE 5 study, treatment with secukinumab (SEC) inhibited radiographic progression and led to sustained remission and low disease activity (LDA) through Week 104. 1,2 Objectives This post hoc analysis of FUTURE 5 explored relationships between radiographic progression status and achievement of LDA or remission in patients treated with SEC. Methods Patients were randomized 2:2:2:3 to receive SEC 300 mg with loading dose (LD), 150 mg LD, SEC 150 mg without LD, or placebo (PBO) at Baseline, Weeks 1, 2, 3, 4, and every 4 weeks thereafter until Week 24. In this post hoc analysis, patients were grouped by radiographic progression status at Week 24 (non-radiographic progressors: change from baseline in modified total Sharp score [mTSS] ≤0.0; radiographic progressors: change from baseline in mTSS &gt;0.0). Efficacy (achievement of Minimal Disease Activity [MDA] or Very Low Disease Activity [VLDA] and their individual components, and Disease Activity Index for Psoriatic Arthritis [DAPSA] LDA or remission) was assessed at Week 24. Results Of 933 patients with available data, 675 (72.3%) were classified as non-radiographic progressors and 258 (27.7%) were radiographic progressors at Week 24. Non-progressors at Week 24 were more likely than progressors to achieve DAPSA LDA and remission at Week 24 across all treatment arms (Figure 1A). In addition, non-progressors were more likely to achieve MDA and VLDA at Week 24 than progressors across all treatment arms (Figure 1B). Similar trends were observed for all of the individual MDA/VLDA criteria at Week 24 among patients treated with SEC 300 mg or SEC 150 mg LD (Table 1). Notably, non-progressors were more likely to achieve improvements in physical function, pain, and patient global assessment of disease activity than progressors across all treatment arms. Table 1. Proportion of Patients Achieving MDA/VLDA Components at Week 24 Grouped by Radiographic Progression Status at Week 24 Week 24 non-progressors Week 24 progressors Outcome, n/N (% ) SEC 300 mg n = 166 SEC 150 mg n = 150 SEC 150 mg NL n = 159 PBO n = 200 SEC 300 mg n = 51 SEC 150 mg n = 63 SEC 150 mg NL n = 51 PBO n = 93 TJC78 ≤1 52/161 (32.3) 46/146 (31.5) 37/150 (24.7) 38/196 (19.4) 15/50 (30.0) 13/62 (21.0) 13/49 (26.5) 11/90 (12.2) SJC76 ≤1 105/160 (65.6) 85/146 (58.2) 83/150 (55.3) 88/196 (44.9) 32/50 (64.0) 28/62 (45.2) 20/49 (40.8) 30/90 (33.3) PASI ≤1 or BSA ≤3% 99/128 (77.3) 90/128 (70.3) 69/109 (63.3) 64/153 (41.8) 29/38 (76.3) 27/47 (57.4) 28/40 (70.0) 26/70 (37.1) Patient pain VAS ≤15 57/144 (39.6) 50/133 (37.6) 50/141 (35.5) 33/179 (18.4) 14/42 (33.3) 15/60 (25.0) 13/43 (30.2) 7/82 (8.5) PtGA VAS ≤20 63/145 (43.4) 47/125 (37.6) 50/135 (37.0) 39/173 (22.5) 13/41 (31.7) 14/61 (23.0) 13/41 (31.7) 7/81 (8.6) HAQ-DI ≤0.5 72/135 (53.3) 55/118 (46.6) 54/122 (44.3) 47/158 (29.7) 13/39 (33.3) 18/58 (31.0) 17/39 (43.6) 19/77 (24.7) Tender entheseal points ≤1 70/87 (80.5) 44/63 (69.8) 42/76 (55.3) 45/88 (51.1) 13/18 (72.2) 17/31 (54.8) 11/19 (57.9) 23/38 (60.5) BSA, body surface area; HAQ-DI, Health Assessment Questionnaire Disability Index; MDA, Minimal Disease Activity; NL, no loading dose; PASI, Psoriasis Area and Severity Index; PBO, placebo; PtGA, patient global assessment of disease activity; SEC, secukinumab; SJC, swollen joint count; TJC, tender joint count; VAS, visual analog scale; VLDA, Very Low Disease Activity. Conclusion Patients who did not have radiographic progression over 6 months of SEC treatment were more likely to achieve LDA or remission and improvement in physical function at Week 24. Additional analyses will explore relationships between radiographic progression and additional clinical and patient-reported outcomes over longer time periods. References [1]Mease P, et al. RMD Open . 2021;7:e001600. [2]Coates LC, et al. Ann Rheum Dis. 2021;80:803-4. Acknowledgements This study was funded by Novartis Pharmaceuticals Corporation. Medical writing support was provided by Eric Deutsch, PhD, CMPP, of Health Interactions, Inc, and was funded by Novartis Pharmaceuticals Corporation. This abstract was developed in accordance with Good Publication Practice (GPP3) guidelines. Authors had full control of the content and made the final decision on all aspects of this publication. Disclosure of Interests Philip J Mease Speakers bureau: AbbVie, Amgen, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galapagos, Gilead, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, and UCB, Ana-Maria Orbai Consultant of: Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB, Grant/research support from: To Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly, and Novartis, Bhumik Parikh Employee of: Novartis Pharmaceuticals Corporation, Corine Gaillez Employee of: Novartis Pharma AG, Xiangyi Meng Employee of: Novartis Pharmaceuticals Corporation, Christopher T. Ritchlin Consultant of: AbbVie, Amgen, Eli Lilly, Janssen, Pfizer, Novartis, Gilead, and UCB